Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alzamend Neuro Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALZN
Nasdaq
8731
https://alzamend.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alzamend Neuro Inc
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
- Dec 11th, 2023 2:30 pm
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
- Dec 11th, 2023 1:00 pm
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
- Nov 20th, 2023 1:00 pm
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
- Nov 16th, 2023 1:00 pm
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
- Nov 13th, 2023 1:00 pm
Alzamend Neuro Announces Reverse Stock Split
- Oct 30th, 2023 12:00 pm
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
- Oct 23rd, 2023 1:31 pm
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
- Oct 23rd, 2023 12:00 pm
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
- Oct 2nd, 2023 1:30 pm
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
- Oct 2nd, 2023 12:00 pm
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
- Sep 22nd, 2023 12:00 pm
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
- Aug 30th, 2023 1:30 pm
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
- Aug 30th, 2023 12:00 pm
We're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
- Aug 24th, 2023 11:23 am
EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
- Jun 22nd, 2023 1:30 pm
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
- Jun 22nd, 2023 12:00 pm
Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare Conference
- Jun 13th, 2023 12:00 pm
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
- May 24th, 2023 12:00 pm
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
- May 11th, 2023 4:38 pm
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
- Apr 4th, 2023 10:30 am
Scroll